Case Report

Convalescent plasma therapy in obese severe COVID-19 adolescents: Two cases report

Citra Cesilia a,*, Elmi Ridar b, Nur Suryawan b, Heda Melinda Nataprawira b

a Department of Child Health, Faculty of Medicine, Riau University – Arifin Achmad General Hospital, Pekanbaru, Indonesia
b Department of Child Health, Faculty of Medicine, Padjajaran University – Dr. Hasan Sadikin, Bandung, Indonesia

ARTICLE INFO

Keywords:
COVID-19
Convalescent plasma therapy
Indonesian children

ABSTRACT

Background: In Indonesia, 175 cases resulted in death in children from March to December 2020. Studies regarding Convalescent Plasma Therapy’s (CPT) safety and efficacy in children are scarce. Our case report was the first to write CPT in Indonesian children.

Case presentation: In our case, two obese children with progressive shortness of breath, worsening cough, and high fever, the findings met severe COVID-19 criteria. We performed CPT for these patients and the patient’s condition was improved and able to be discharged.

Discussion: Severe COVID-19 with or without comorbid was the indication of CPT which had been approved by the U.S. FDA and Indonesian Pediatrics Society. The key factors associated with CPT efficacy were the donor’s titer antibody, the treatment time point, and the patient’s comorbidities. The clinical impact showed an improvement by the combination therapy of CPT and remdesivir.

Conclusion: We noted that CPT might be well tolerated, could improve the clinical impact of severe COVID-19 in adolescents, and have no adverse events as well. CPT for severe COVID-19 cases in children had the potential to be developed in studies with better designs and stronger levels of evidence.

1. Introduction

In Indonesia, 175 cases resulted in the death of a total of 37,706 confirmed COVID-19 cases in children from March to December 2020, the highest mortality was aged 10–18 years [1]. Antivirals are given selectively to pediatric patients with confirmed severe or moderate degrees of COVID-19 accompanied by comorbidities [2]. Some adjuvant therapies given to adults are not necessarily applicable to children because of limited studies on this matter [3,4]. The use of Convalescent Plasma Therapy (CPT) has been proven successful in several adult COVID-19 patients [5]. Few studies regarding CPT’s safety and efficacy in children were found and only in case reports or case series. However, some studies include the adolescent age group, only a few moderate or severe cases received CPT [6,7]. Based on the description above, we report two cases of COVID-19 in children who received the first CPT reported in Indonesia. The report is based on the Surgery Case Report (SCARS) 2020 Guideline [8].

2. Case presentation

2.1. Case 1

A 10-year-old obese boy weighing 60 kg was referred after being treated for eight days in a type D hospital for ICU admission due to rapidly progressing acute respiratory failure due to COVID-19. The patient had been commencing favipiravir for three days. The patient presented with progressively shortness of breath, worsening cough, and high fever for three days. The patient had close contact with the confirmed COVID-19 mother. The patient was febrile, tachycardia, tachypnea, and respiratory distress. The chest radiograph (CXR) and chest CT-Scan were performed (Fig. 1). Laboratory findings on admission showed lymphopenia, elevated alanine aminotransferase (ALT), C-reactive protein (CRP), Interleukin-6 (IL-6), ferritin, and D-dimer. Blood gas analysis (BGA) showed a fully compensated metabolic acidosis with severe hypoxemia. Following medium-flow nasal oxygen (15 L/min, FiO2 100%) for 12 hours, his condition had not improved.

Therefore, the patient was started on non-invasive ventilation (NIV)

https://doi.org/10.1016/j.amsu.2021.103084
Received 30 October 2021; Received in revised form 15 November 2021; Accepted 16 November 2021
Available online 18 November 2021
2049-0801/© 2021 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license
Demographics and clinical characteristics.

Table 1

| Patient | Case 1 | Case 2 |
|---------|--------|--------|
| Age     | 10.7   | 17.7   |
| Sex     | Male   | Female |
| BMI     | 27.8   | 32.4   |
| Ethnicity | Malaysia | Batak |
| Comorbidities | Obesity, asthma | Obesity |
| O2 Support | NIV PEEP 5, 100% | Non-rebreathing mask, O2 15 L/Min |
| Hospital LOS | 10      | 10     |
| Hospital day of CCP | 2    | 3     |
| CCP units transfused | 400  | 400  |
| Additional therapies | Remdesivir, Methylprednisolone, LMWH | Remdesivir, Methylprednisolone, LMWH |
| Outcome | Discharge home 6d after CCP | Discharge home 5d after CCP |
| Laboratory at admission | C-reactive protein (mg/L) | 35.6 | 131 |
| Interleukin-6 | 28.32 | N/A |
| Ferritin (ng/mL) | 845.16 | N/A |
| Lactate dehydrogenase (U/L) | N/A | 692 |
| D-Dimer (ng/mL) | 608.1 | 1320 |
| WBC | 10,040 | 6810 |
| Lymphocyte (×10³/μL) | 18.5 | 17.2 |
| Platelet count (×10³/μL) | 395,000 | 293,000 |
| Aspartate aminotransferase (U/L) | 225/495 | 64/42 |
| Alanine aminotransferase (U/L) | B+ | A+ |
| pH | 7.41 | 7.34 |
| pCO2 | 49 | 42 |
| pO2 | 56 | 52 |
| HCO3 | 30.1 | 23 |
| BE | 4.1 | −3 |
| SpO2 | 88 | 84 |

mg/kg/day, and four units (2 × 400 mL) of CPT for two days was given on day 2 in our hospital. The improvement was noted of inflammatory markers and D-dimers on day 4. The patient could wean from NIV to NRM on day 6. The patient was stable on room air on day 8. The patient was discharged home on day 10 after undergoing physiotherapy and negative PCR results from two consecutive times (Fig. 2).

2.2. Case 2

A 17-year-9-month-old obese teenage girl weighing 72 kg presented to Emergency Unit due to progressive shortness of breath for three days. For seven days, the complaint was preceded by fever, cough, rhinorrhea, chest pain, malaise, and nausea. We could not identify the case index of COVID-19 from close household contact. The patient was alert, tachycardia with normal blood pressure and perfusion, respiratory distress, rhonchi in both lung fields, and 80% oxygen saturation in room air. The CXR and chest CT-Scan was performed (Fig. 3). Laboratory results were showed lymphopenia, elevated CRP, LDH, D-Dimers, slightly elevated ALT, and BGA results showed fully compensated metabolic acidosis with severe hypoxemia (Table 1).

The patient received 200 mg for two days which are given on the third days of hospitalization. Following CPT initiation of remdesivir, the patient had improvement in laboratory value and oxygen requirement on day 6. In addition, the CXR showed infiltrate improvement. The patient was discharged on day 10 after undergoing physiotherapy, and PCR examination showed negative results two consecutive times (Fig. 1).

3. Discussion

Studies regarding CPT’s safety and efficacy in children are minimal and are only in case reports or case series. A case series of 4 patients admitted to the PICU diagnosed with COVID-19 and ARDS who required a high flow nasal cannula at admission. All patients had a complete recovery and found no adverse effect from CPT [6]. In late 2020, a systematic review about the use of CPT in children was published and concluded that the efficacy of CPT was still uncertain due to the limited number of samples [2].

CPT is classic adoptive immunotherapy that has been given to prevent and treat many infectious diseases for more than one century [9]. CPT obtained from recovered COVID-19 patients who had established humoral immunity against the virus contains many neutralizing antibodies that can neutralize SARS-CoV-2 and eradicate the pathogen from the blood circulation and pulmonary tissues [10]. Antibodies from donor plasma can bind to SARS-CoV-2 and exhibit neutralizing properties directly or through other mechanisms, such as complement activation, antibody-dependent cellular cytotoxicity, and phagocytosis [10, 11]. It accelerates the healing process when administrated prophylactically or immediately after symptom onset [12,13]. Thus, the administration of passive antibodies is a short-term strategy to provide immediate immunity to susceptible individuals [11]. Things to watch out for and monitor after convalescent plasma therapy are possible side effects: transfusion-related lung injury (TRALI), transfusion-associated circulatory overload (TACO), and anaphylaxis [6].

In the United States, CPT is given through the Emergency Use Authorization (EUA) from the FDA. However, the safety and effectiveness of CPT in the pediatric patient population have not been evaluated [14]. The Indonesian Pediatric Society (IPS) recommends giving convalescent plasma therapy for children weighing >40 kg at a dose of 200–500 mL and a dose of 10–15 mL/kg BW for children weighing <40 kg [15]. There are three critical factors associated with CPT efficacy. Firstly, the neutralizing antibody titer [9,12]. Therefore, it is necessary to find eligible donors who have high levels of neutralizing antibodies.
Secondly, the treatment time point. Data from other respiratory infections suggest that convalescent plasma provides the most practical effect early in the disease process [9]. Thirdly, the presence of comorbidities in inpatients. The earlier the administration of convalescent plasma therapy will be very beneficial for managing severe and critical COVID-19, but comorbid diseases will significantly affect the prognosis of COVID-19 in children, which requires further research [12].

Both of our patients had obesity as a comorbidity. Obesity is a common metabolic disorder globally [13]. It has been reported that obese patients are more vulnerable to COVID-19 and have a higher risk of worse clinical outcomes [15,16]. Several hypotheses may explain the relationship between obesity and severe COVID-19. Obesity, characterized by adipose tissue (AT) expansion that affects the inflammatory response [17–20]. Cytokine storm is the hyperactivation of the inflammatory response with elevated interferon γ, IL-6, and other pro-inflammatory cytokines also aggravate COVID-19 severity [17]. In addition to this, severe patients appeared to have a higher portion of CD14+CD16− inflammatory monocytes than non-severe patients, suggesting an elevated inflammation level in severe COVID-19 patients [19,20]. The weakened immune system in obese patients may lead to higher viral load, rapid viral replication, and spreading [17,19,20].

The limitations of this study are the small number of participants and the comparison of giving CPT to COVID-19 patients. Future studies are expected to complement the limitations of our report.

4. Conclusion

We note that CPT at a dose of two or more 200-mL, with combination therapy, might be likely well tolerated and could improve the clinical impact of severe COVID-19 cases in adolescents with no adverse events identified. The optimal dose, time point, and comorbidities are the key for the clinical benefit of CPT need further study in more extensive, well-controlled trials. The CPT with the combination of remdesivir and steroid may have led to a rapid resolution of the infection.

Ethical approval

We have conducted an ethical approval base on Declaration of Helsinki at Ethical Committee.

Sources of funding

None.

Author contribution

All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work.

Registration of research studies

Not applicable.

Guarantor

Citra Cesilia.

Consent

Written informed consent was obtained from the patient or guardian for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this
Acknowledgment

Declaration of competing interest

The author declare that they have no conflict of interest.

Acknowledgment

We would like to thank Fis Citra Ariyanto as our editor.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2021.103084.

References

[1] A.H. Pudjiadi, N.D. Putri, H.A. Sjakti, P.B. Yanauso, H. Gunardi, R.D. Roestani, et al., Pediatric COVID-19: report from Indonesian pediatric society data registry, Front. Pediatr. 9 (2021) 716898, https://doi.org/10.3389/fped.2021.716898.

[2] M. Zaffanello, G. Piacentini, L. Nosetti, M. Franchini, The use of convalescent plasma for pediatric patients with SARS-CoV-2: a systematic literature review, Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapheresis 60 (2) (2021) 103043, https://doi.org/10.1016/j.trasci.2020.103043.

[3] L.S. Shekerdemian, L.R. Mahmood, K.K. Wolf, B.J. Riggs, C.E. Ross, C.A. McKiernan, et al., Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units, JAMA Pediatr. 174 (9) (2020) 868–873, https://doi.org/10.1001/jamapediatrics.2020.1948.

[4] D.M. Fernandes, C.R. Oliveira, S. Guerquis, R. Eisenberg, J. Choi, M. Kim, et al., Severe acute respiratory syndrome coronavirus 2 clinical syndromes and predictors of disease severity in hospitalized children and youth, J. Pediatr. 230 (2021) 23–31, https://doi.org/10.1016/j.jpeds.2021.01.016.

[5] M.R. Salazar, S.E. González, L. Reguáriz, N.S. Ferrando, V.V. González Martínez, P. M. Carrera Ramos, et al., Risk factors for COVID-19 mortality: the effect of convalescent plasma administration, PloS One 16 (4) (2021), e0250386, https://doi.org/10.1371/journal.pone.0250386.

[6] S.P. Schwartz, P. Thompson, M. Smith, D.M. Lercher, C.A. Rimland, L. Bartelt, et al., Convalescent plasma therapy in critically ill pediatric patients with coronavirus disease 2019: a case series, Crit. Care Explor. 2 (10) (2020), e0237, https://doi.org/10.1097/cccc.0000000000002137.

[7] C. Turan, E.G. Basa, D. Elitez, O. Yilmaz, E. Gümüş, M. Anil, The comparison of children who were diagnosed with COVID-19 in the first and the second waves of the SARS-CoV-2 pandemic, Turk. Arch. Pediatr. 56 (6) (2021) 596–601, https://doi.org/10.5152/TurkArchPediatr.2021.21162.

[8] R.A. Ágha, T. Franchi, C. Sohrabi, G. Mathew, A. Kervan, The SCARE 2020 guideline: updating consensus surgical Case Report (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230, https://doi.org/10.1016/j.ijsu.2020.10.034.

[9] J.H. Ko, H. Seok, S.Y. Cho, Y.E. Ha, J.Y. Baek, S.H. Kim, et al., Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience, Antivir. Ther. 23 (7) (2018) 617–622, https://doi.org/10.3851/imp245.

[10] L. Li, W. Zhang, Y. Hu, X. Tong, S. Zheng, J. Yang, et al., Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA 324 (5) (2020) 460–470, https://doi.org/10.1001/jama.2020.10044.

[11] V.A. Simonovich, L.D. Burgos Pratz, P. Scibona, M.V. Beruto, M.G. Vallone, C. Vázquez, et al., A randomized trial of convalescent plasma in covid-19 severe pneumonia, N. Engl. J. Med. 384 (7) (2021) 619–629, https://doi.org/10.1056/NEJMoa2031304.

[12] Z. Rodriguez, A.L. Shane, H. Verkerke, C. Lough, M.G. Zimmerman, M. Suthar, et al., COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease, Blood Adv. 4 (18) (2020) 4278–4281, https://doi.org/10.1182/bloodadvances.2020002507.

[13] X. Zhu, L. Yang, K. Huang, COVID-19 and obesity: epidemiology, pathogenesis and treatment, Diabetes, Metab. Syndr. Obes. Targets Ther. 13 (2020) 4953–4959, https://doi.org/10.2147/dmso.S285197.

[14] R. Gharooy, E.P. Krenzelok, US food and drug administration (FDA) emergency use authorization: glass half full or glass half empty? Clin. Infect. Dis.: Off. Pub. Infect. Dis. Soc. Am. 73 (3) (2021) 549–552, https://doi.org/10.1093/cid/ciaa1653.

[15] M.S. Rejeki, N. Sarnadi, R. Wiharista, V. Fachbaryati, W.W. Samin, F.A. Yudhaputri, et al., Convalescent plasma therapy in patients with moderate-to-severe COVID-19: a study from Indonesia for clinical research in low- and middle-income countries, EClinicalMedicine 36 (2021) 100931, https://doi.org/10.1016/j.eclinm.2021.100931.

[16] K.I. Zheng, F. Gao, X.B. Wang, Q.F. Sun, K.H. Pan, T.Y. Wang, et al., Letter to the Editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease, Metab. Clin. Exp. 108 (2020) 154244, https://doi.org/10.1016/j.metabol.2020.154244.

[17] H.S. Park, J.Y. Park, R. Yu, Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6, Diabetes Res. Clin. Pract. 69 (1) (2005) 29–35, https://doi.org/10.1016/j.diabres.2004.11.007.

[18] R. Divella, R. De Luca, I. Abbate, E. Naglieri, A. Daniele, Obesity and cancer: the role of adipose tissue and adipocytokines-induced chronic inflammation, J. Cancer 17 (5) (2016) 2346–2359, https://doi.org/10.7150/jca.16884.

[19] Y. Shi, Y. Wang, C. Shao, J. Huang, J. Gan, X. Huang, et al., COVID-19 infection: the perspectives on immune responses, Cell Death Differ. 27 (5) (2020) 1451–1454, https://doi.org/10.1038/s41418-020-0530-3.

[20] G. Muscogiuri, G. Pugliese, L. Barrea, S. Savastano, A. Colao, Commentary: obesity the "achilles heel" for COVID-19? Metabolism, Clin. Exp. 108 (2020) 154251, https://doi.org/10.1016/j.metabol.2020.154251.